Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease

被引：0
|
作者：
Sako, M. [1 ]
Kawaguchi, T. [1 ]
Hirayama, A. [1 ]
Fukushi, G. [1 ]
Hayama, K. [1 ]
Fujiwara, T. [1 ]
Yoshimura, N. [1 ]
Takazoe, M. [1 ]
机构：
[1] Social Insurance Cent Hosp, Ctr Inflammatory Bowel Dis, Tokyo, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60517-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P397
引用
收藏
页码：S231 / S231
页数：1
相关论文
共 50 条
  • [31] Durability of Infliximab Dose Intensification in Crohn's Disease
    Lin, Kirk
    Terdiman, Jonathan E.
    GASTROENTEROLOGY, 2010, 138 (05) : S695 - S695
  • [32] Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
    Bultman, E.
    de Haar, C.
    van Liere-Baron, A.
    Verhoog, H.
    West, R. L.
    Kuipers, E. J.
    Zelinkova, Z.
    van der Woude, C. Janneke
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (03) : 335 - 341
  • [33] Recommendations for Dose Adjustments of Infliximab in Crohn's Disease Patients with Higher Clearance
    Andersson, Helena
    Eser, Akexander
    Huisinga, Wilhelm
    Reinisch, Walter
    Kloft, Charlotte
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S27 - S27
  • [34] Population pharmacokinetics of single dose infliximab in patients with Crohn's disease.
    Fasanmade, AA
    Zhu, YW
    Wagner, C
    Pendley, C
    Davis, HM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P66 - P66
  • [35] Outcomes After Dose Intensification of Risankizumab for Crohn's Disease
    Dalal, Rahul s.
    Cabral, Heidy j.
    Carlin, Alex
    Ilse, Matthew p.
    Allegretti, Jessica r.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2025, 23 (04)
  • [36] Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease
    Brown, Peter
    Clark, Tanya
    Dowson, Grace
    Warren, Lisa
    Hamlin, John
    Hull, Mark
    Subramanian, Venkataraman
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (10): : 1144 - 1150
  • [37] Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab vs. Infliximab in the United States
    Khalid, Javaria Mona
    Raluy-Callado, Mireia
    Li, Qian
    Luo, Michelle
    Lasch, Karen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S316 - S317
  • [38] Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab Levels
    Allegretti, Jessica R.
    Carrellas, Madeline
    Hamilton, Matthew
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2016, 150 (04) : S421 - S421
  • [39] Desensitisation to infliximab in patients with Crohn's disease
    Lelong, J
    Duburque, C
    Fournier, C
    Colombel, JF
    Desreumaux, P
    Tonnel, AB
    Wallaert, B
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (02) : 239 - 246
  • [40] Long term outcomes following de-escalation of dose-intensified ustekinumab in patients with Crohn's disease
    Demase, K.
    Smith, R. L.
    Luber, R.
    Taylor, K. M.
    Ward, M. G.
    Sparrow, M. P.
    Little, R. D.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1317 - I1317
12345